Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIGH-LIGHT: Bevacizumab Strategies in Metastatic Colorectal Cancer
NCT02842580Phase 2Terminated
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Sep 2016
- Primary completion
- Oct 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in colorectal cancer (metastatic) (mCRC) (2 arms), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: Percentage of Patients Without Failure of the Strategy at 16 months. Started Sep 2016; status: terminated.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT02842580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02842580.